CLINUVEL PHARMACEUTICALS LTD

CLINUVEL PHARMACEUTICALS LTD We are a global specialty pharmaceutical group focused on developing and commercialising treatments

15/07/2025

Desiree Lyon, co-founder of the American Porphyria Foundation (APF) is one of the pioneers of the 1983 Orphan Drug Act, incentivising the development of treatments for rare diseases.

Her work with the APF has allowed for further awareness of porphyria amongst healthcare professionals, leading to better outcomes for patients.

It is a privilege for CLINUVEL to support the APF’s mission to empower people living with porphyria and increase access to treatment options.

11/07/2025

The American Porphyria Foundation’s Executive Director Nicole Castellano knows first-hand what it is like to live with porphyria.

This group of rare inherited disorders is difficult to diagnose as symptoms can mimic other illnesses that are more common.
Raising awareness of porphyria amongst the public and healthcare professionals may help reduce the time taken to receive an accurate diagnosis.

The United States Centers for Disease Control and Prevention (CDC) observes July as National Minority Mental Health Awar...
10/07/2025

The United States Centers for Disease Control and Prevention (CDC) observes July as National Minority Mental Health Awareness Month. The initiative aims to raise awareness of the challenges impacting the mental health of people in ethnic minority groups.

Research by Jean-Pierre et al suggests that vitiligo patients from ethnic minority groups experience a greater mental health burden than their white counterparts, with 50% of Black participants and 44% of Hispanic participants reporting symptoms of depression, compared to 34% of white participants.

CLINUVEL continues to advocate for a comprehensive approach to vitiligo care that aims to improve mental wellbeing alongside physical health.

07/07/2025

“How did they get it so wrong?”

Recent reports from Australian consumer group Choice have shown that many solar protection products do not meet their labelled sun protection factor (SPF) claim.

CLINUVEL’s Regulatory Affairs Project Manager (Cosmetics), Alice Lynn joins Sarah Mawson to discuss SPF, product testing and why some labels may not be what they seem.

Listen to the podcast here: https://www.youtube.com/watch?v=PWiHPZ02JsA

05/07/2025

On , we are highlighting the importance of clinical research and the positive impact it can have on individuals worldwide.

Clinical research deepens our understanding of the diseases we aim to treat and fuels the development of new therapies.
CLINUVEL is dedicated to translating scientific breakthroughs into innovative potential treatment options for the unmet needs of patients with conditions such as erythropoietic protoporphyria ( ) and vitiligo.

Learn more about our areas of focus here: https://www.clinuvel.com/pharmaceuticals/disease-entities/

04/07/2025

The CLINUVEL team looks forward to attending the Arthur Cox Life Sciences Symposium in Dublin, Ireland.

Today’s event features sessions discussing access to medicines, the European health data space and pharmaceutical law within the EU.

Staying up-to-date with the latest regulations, ensuring strict compliance to pharmaceutical laws around the world and increasing access to treatment remain important priorities to CLINUVEL.

In the United Kingdom, July is celebrated as National Picnic Month. It is a time for the public to enjoy time with famil...
03/07/2025

In the United Kingdom, July is celebrated as National Picnic Month. It is a time for the public to enjoy time with family and friends outdoors, sharing the joys of picnicking.

This can mean spending hours exposed to the powerful UV rays emitted from sunlight. UV radiation can cause photodamage, increase the risk of sunburn, and contribute to long-term health issues like skin cancer.

Applying high factor topical solar protection regularly when outdoors is crucial to reducing the harmful effects of solar radiation.

CLINUVEL’s latest vitiligo announcement highlights the current vitiligo treatment landscape, observations from the CUV10...
02/07/2025

CLINUVEL’s latest vitiligo announcement highlights the current vitiligo treatment landscape, observations from the CUV105 clinical trial and how the Company’s commercial infrastructure is being built to address a larger patient population.

Read the announcement here: https://brnw.ch/21wTQmr

01/07/2025

Porphyrias are a group of rare inherited disorders which are often misdiagnosed due to a lack of awareness amongst healthcare professionals.

CLINUVEL supports the American Porphyria Foundation’s (APF) mission to increase education and empower those living with porphyria.

The APF’s Executive Director Nicole Castellano shares her personal experience of the diagnostic odyssey faced by many with porphyria.

The UV Index (UVI) is a measure of solar UV ultraviolet radiation at the Earth’s surface in terms of potential damage to...
30/06/2025

The UV Index (UVI) is a measure of solar UV ultraviolet radiation at the Earth’s surface in terms of potential damage to the skin and the eyes.

When the UVI is higher, it takes less time for harm to occur to your skin.

Protecting your skin from harmful UV with topical photoprotection, protective clothing, and avoiding prolonged sun exposure is crucial for maintaining healthy skin and preventing photodamage.

Today is  , a day aiming to improve the quality of life for individuals with vitiligo through education, research, clini...
25/06/2025

Today is , a day aiming to improve the quality of life for individuals with vitiligo through education, research, clinical care, and community support.

Visibly, vitiligo causes depigmented patches of skin (vitiliginous lesions) to appear on different parts of the body due the lack of melanin (pigment).

Vitiligo impacts more than just the skin, often posing a heavy emotional burden affecting identity, self-esteem, relationships and careers.

CLINUVEL is investigating afamelanotide as a potential treatment for vitiligo.

Learn more about CLINUVEL’s CUV105 vitiligo study here: https://brnw.ch/21wTFeM

24/06/2025

The Global Vitiligo Foundation’s Camp Victory will be taking place over 24–26 June in Tampa, Florida.

This initiative is dedicated to bringing joy and empowerment into the lives of children with and their families.
Global Vitiligo Foundation President and CLINUVEL Non-executive Director Dr Pearl Grimes is a dedicated member of the team behind Camp Victory, with a long-running commitment to empowering at-risk youth as well as children living with vitiligo.

CLINUVEL is proud to support Dr Grimes and the Global Vitiligo Foundation’s efforts to empower people worldwide living with vitiligo.

Address

Melbourne

Alerts

Be the first to know and let us send you an email when CLINUVEL PHARMACEUTICALS LTD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to CLINUVEL PHARMACEUTICALS LTD:

Share